Next Science Limited Stock Analysis
| NXSCF Stock | USD 0.01 0.01 50.00% |
Next Science Limited holds a debt-to-equity ratio of 0.093. Next Science's financial risk is the risk to Next Science stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Next Science's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Next Science's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Next Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Next Science's stakeholders.
For many companies, including Next Science, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Next Science Limited, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Next Science's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Next Science's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Next Science is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Next Science to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Next Science is said to be less leveraged. If creditors hold a majority of Next Science's assets, the Company is said to be highly leveraged.
Next Science Limited is fairly valued with Real Value of 0.0144 and Hype Value of 0.02. The main objective of Next Science pink sheet analysis is to determine its intrinsic value, which is an estimate of what Next Science Limited is worth, separate from its market price. There are two main types of Next Science's stock analysis: fundamental analysis and technical analysis.
The Next Science pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Next Science's ongoing operational relationships across important fundamental and technical indicators.
Next |
Next Pink Sheet Analysis Notes
About 53.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.05. Next Science Limited had not issued any dividends in recent years. Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia. Next Science operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.The quote for Next Science Limited is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Next Science Limited contact Judith MBA at 61 2 8607 5126 or learn more at https://www.nextscience.com.Next Science Limited Investment Alerts
| Next Science Limited had very high historical volatility over the last 90 days | |
| Next Science Limited has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 8.95 M. Net Loss for the year was (9.35 M) with profit before overhead, payroll, taxes, and interest of 6.94 M. | |
| Next Science Limited has accumulated about 11.06 M in cash with (8.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 53.0% of the company outstanding shares are owned by corporate insiders |
Next Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 112.89 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Next Science's market, we take the total number of its shares issued and multiply it by Next Science's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Next Profitablity
The company has Profit Margin (PM) of (1.12) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.14) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.14.Technical Drivers
As of the 10th of February, Next Science secures the Risk Adjusted Performance of 0.0567, downside deviation of 45.51, and Mean Deviation of 7.67. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Next Science Limited, as well as the relationship between them. Please verify Next Science Limited downside deviation and the relationship between the information ratio and expected short fall to decide if Next Science Limited is priced some-what accurately, providing market reflects its recent price of 0.015 per share. As Next Science Limited appears to be a penny stock we also strongly suggest to check its total risk alpha numbers.Next Science Limited Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Next Science price series with the more recent values given greater weights.
Next Science Predictive Daily Indicators
Next Science intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Next Science pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.5 | |||
| Day Median Price | 0.015 | |||
| Day Typical Price | 0.015 | |||
| Price Action Indicator | 0.0025 | |||
| Period Momentum Indicator | 0.005 |
Next Science Forecast Models
Next Science's time-series forecasting models are one of many Next Science's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Next Science's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Next Science Limited Debt to Cash Allocation
Many companies such as Next Science, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Next Science Limited has accumulated 1.34 M in total debt with debt to equity ratio (D/E) of 0.09, which may suggest the company is not taking enough advantage from borrowing. Next Science Limited has a current ratio of 5.29, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Next Science until it has trouble settling it off, either with new capital or with free cash flow. So, Next Science's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Next Science Limited sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Next to invest in growth at high rates of return. When we think about Next Science's use of debt, we should always consider it together with cash and equity.Next Science Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Next Science's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Next Science, which in turn will lower the firm's financial flexibility.About Next Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Next Science prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Next shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Next Science. By using and applying Next Pink Sheet analysis, traders can create a robust methodology for identifying Next entry and exit points for their positions.
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia. Next Science operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Next Science to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Comparator Now
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account |
| All Next | Launch Module |
Complementary Tools for Next Pink Sheet analysis
When running Next Science's price analysis, check to measure Next Science's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Next Science is operating at the current time. Most of Next Science's value examination focuses on studying past and present price action to predict the probability of Next Science's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Next Science's price. Additionally, you may evaluate how the addition of Next Science to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |